CERTAIN CONFIDENTIAL INFORMATION IN THIS EXHIBIT WAS OMITTED BY MEANS OF MARKING SUCH INFORMATION WITH BRACKETS (“[***]”) BECAUSE THE IDENTIFIED CONFIDENTIAL INFORMATION IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR...

Exhibit 4.5

CERTAIN CONFIDENTIAL INFORMATION IN THIS EXHIBIT WAS OMITTED BY MEANS OF MARKING
SUCH INFORMATION WITH BRACKETS (“[***]”) BECAUSE THE IDENTIFIED CONFIDENTIAL
INFORMATION IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

Clinical Trial Research Agreement

Medicines Australia - Standard Form

Details of the parties

Name of Institution:	Xxxxxx Health a body corporate established under the Health Services Xxx 0000 (Vic) of Xxxxxxxxxx Xxxx, Xxxxxxxxx, 0000 or Xxxxxx Health
Address:	Xxxxxxxxxx Xxxx, Xxxxxxxxx, Xxxxxxxx, 0000
ABN:	00 000 000 000
Contact for Notices:	Xxxxxxxxx Xxxxxxx X’Xxxxx
Fax for Notices:	[***]
Phone Number:	[***]

Name of Sponsor:	lncannex Healthcare Ltd
Address:	0 Xxx Xxxxxx
	Xxxxxxx Xxxxxxx, 0000 Xxxxxxxx Xxxxxxxxx
ABN:	00 000 000 000
Contact for Notices:	Xx Xxxx Xxxxxx
Fax for Notices:	NIA
Phone Number:	[***]

Study Name:	Dose finding crossover trial investigating the effect of dronabinol combined with acetazolamide on Apnoea Hypopnea Index (AHi) in adults with obstructive sleep apnoea (OSA)
Protocol Number:	IHLOSAPOC1
Date of Agreement:	As per date of full execution

Protocol Number: IHLOSAPOC1 Site: Xxxxxx Health
Medicines Australia Standard CTRA 8 March 2017 (revised)	Page 1 of 38

This agreement is made between the Sponsor and Institution

Purpose of the Agreement

According to this Agreement:

A. The Sponsor is responsible for the initiation, management, and financing of the Study.

B. The Institution, through the Principal Investigator, is responsible for the conduct of the Study at the Study Site(s) which is/are under the control of the Institution.

C. The Study will be conducted on the terms and conditions set out below.

Operative Provisions

1. INTERPRETATION

1.1 In this Agreement:

Adverse Event has the meaning given in the TGA document “Access to Unapproved Therapeutic Goods – Clinical Trials in Australia” (October 2004) or its replacement.

Affiliate means any company which (directly or indirectly) controls, is controlled by or is under common control with the Sponsor.

Agreement means this Agreement, including all the Schedules.

Background Intellectual Property (Background IP) of a party means information, techniques, know-how, software and materials (regardless of the form or medium in which they are disclosed or stored) that are provided by or on behalf of that party to the other for use in the Study (whether before or after the date of this Agreement) or used by that other party in conducting the Study, and all Intellectual Property in them, but excludes the Study Materials.

Biological Samples means any physical samples obtained from Study Participants in accordance with the Protocol for the purposes of the Study.

Case Report Form means a printed, optical or electronic document or database designed to record all of the information, which is required by the Protocol to be reported to the Sponsor on each Study Participant.

Confidential Information means:

(1) in respect of the Sponsor:

(a) all information collected in the course of, resulting from, or arising directly out of the conduct of the Study, whether at the Study Site or elsewhere;

(b) the Protocol, the Investigator’s Brochure, information related to the Protocol, Study Materials and Investigational Product;

(c) know-how, trade secrets, ideas, concepts, technical and operational information, scientific or technical processes or techniques, product composition or details owned by the Sponsor or its Affiliates;

(d) know-how, methodology, trade secrets, processes, sequences, structure and organisation of the Study; and

(e) information concerning the business affairs or clients of the Sponsor or its Affiliates;

Protocol Number: IHLOSAPOC1 Site: Xxxxxx Health
Medicines Australia Standard CTRA 8 March 2017 (revised)	Page 2 of 38

(2) in respect of the Institution, information in relation to the Institution’s business, operations or strategies, intellectual or other property or actual or prospective suppliers or competitors, but Confidential Information does not include Personal Information.

Equipment means the equipment supplied to the Institution by or on behalf of the Sponsor for the purposes of the Study, including that specified in Schedule 1.

Essential Documents means documents which individually and collectively permit evaluation of the conduct of the Study and the quality of the data produced.

GCP Guideline means the Committee for Proprietary Medicinal Products (CPMP)/lnternational Conference on Harmonisation (ICH) Note for Guidance on Good Clinical Practice (CPMP/ICH/135/95) as adopted with annotation by the TGA, or its replacement.

GST means the Goods and Services Tax payable under a GST Law.

GST Law means the same as in A New Tax System (Goods and Services Tax) Xxx 0000 (Cth) as amended from time to time, and any regulations made pursuant to that Act.

Institution means the body so described on the first page of this Agreement.

Intellectual Property means all present and future industrial and intellectual property rights, including without limitation:

(1) inventions, patents, copyright, trade business, company or domain names, rights in relation to circuit layouts, plant breeders rights, registered designs, registered and unregistered trade marks, know how, trade secrets and the right to have confidential information kept confidential, and any and all other rights to intellectual property which may subsist anywhere in the world; and

(2) any application for or right to apply for registration of any of those rights.

Investigational Product is the medicine or device being trialled or tested in the Study, as set out in Schedule 1, and includes where relevant any placebo.

Investigator’s Brochure is a compilation of the clinical and non-clinical data on the Investigational Product(s) which are relevant to the study of the Investigational Product in humans.

Multi-centre Study is a Study conducted by several investigators according to a single protocol at more than one study site.

NHMRC means the National Health and Medical Research Council of the Commonwealth of Australia.

Personal Information has the same meaning as in the Privacy Xxx 0000 (Cth).

Personnel means employees, agents and/or authorized representatives, and includes, in the case of the Institution, the Principal Investigator.

Principal Investigator is the person responsible for the conduct of the Study at the Study Site as described in Schedule 1.

Protocol means the document identified in Schedule 6 which describes the objective(s}, design, methodology, statistical considerations and organisation of the Study, and subject to clause 2.3, as amended from time to time, as agreed by the parties, and most recently approved by the Reviewing HREC.

Publish means to publish, by way of a paper, article, manuscript, report, poster, internet posting, presentation slides, abstract, outline, video, instruction material or other disclosure, the Study Materials, in printed, electronic, oral or other form.

Publication has a corresponding meaning.

Protocol Number: IHLOSAPOC1 Site: Xxxxxx Health
Medicines Australia Standard CTRA 8 March 2017 (revised)	Page 3 of 38

Regulatory Authority means any body which has jurisdiction over the conduct of the Study at the Study Site and includes the TGA and any overseas regulatory authorities who may audit, or require to be audited, any part of the Study or Study Materials.

Relevant Privacy Laws means the Privacy Xxx 0000 (Cth) and any other legislation, code or guideline which applies in the jurisdiction in which the Study Site is located, and which relates to the protection of Personal Information.

Reviewing HREC means the Human Research Ethics Committee reviewing the Study on behalf of the Institution as described in Schedule 1.

Serious Adverse Event has the meaning given in the TGA document “Access to Unapproved Therapeutic Goods – Clinical Trials in Australia” (October 2004) or its replacement.

Software means the software supplied to the Institution by or on behalf of the Sponsor for the purposes of the Study, including that specified in Schedule 1.

Sponsor means the corporate entity so described on the first page of this Agreement.

Study means the investigation to be conducted in accordance with the Protocol.

Study Completion means the database for the Study has been locked and all Essential Documents have been provided to the Sponsor, including a copy of the letter from the Reviewing HREC acknowledging receipt of the final report and/or closure letter from the Principal Investigator.

Study Materials means all the materials and information created for the Study, or required to be submitted to the Sponsor including all data, results, Biological Samples, Case Report Forms (or their equivalent) in whatever form held, conclusions, discoveries, inventions, know-how and the like, whether patentable or not, relating to the Study, which are discovered or developed as a result of the Study, but excluding the Institution’s ordinary patient records.

Study Participant means a person recruited to participate in the Study.

Study Site means the location(s) under the control of the Institution where the Study is actually conducted as set out in Schedule 1.

TGA means the Therapeutic Goods Administration of the Commonwealth of Australia or any successor body.

1.2 Except where the context otherwise requires:

(1) clause headings are for convenient reference only and are not intended to affect the interpretation of this Agreement;

(2) where any word or phrase has a defined meaning, any other form of that word or phrase has a corresponding meaning;

(3) any reference to a person or body includes a partnership and a body corporate or body politic;

(4) words in the singular include the plural and vice versa;

(5) all the provisions in any schedule to this Agreement are incorporated in, and form part of, this Agreement and bind the parties;

(6) a reference to a replacement of a document or standard, means any document or ruling which amends, updates, replaces or supersedes that document or standard;

(7) if a period of time is specified and dates from a given day or the day of an act or event, it is to be calculated inclusive of that day;

Protocol Number: IHLOSAPOC1 Site: Xxxxxx Health
Medicines Australia Standard CTRA 8 March 2017 (revised)	Page 4 of 38

(8) a reference to a monetary amount means that amount in Australian currency; and

(9) references to a party include its Personnel.

2. THE STUDY

2.1 The parties must comply with, and conduct the Study in accordance with, the Protocol and any conditions of the Reviewing HREC. In addition the parties must comply with the following, as applicable:

(1) any requirements of relevant Commonwealth or State or Territory laws or of Regulatory Authorities;

(2) the requirements of the TGA in Access to Unapproved Therapeutic Goods – Clinical Trials in Australia (October 2004) or its replacement and any other TGA publication or guideline that relates to clinical trials, or other such regulations or guidance governing the conduct of clinical research in the jurisdiction of the Study;

(3) the GCP Guideline;

(4) the principles that have their origins in the Declaration of Helsinki adopted by the World Medical Association in October 1996 (as accepted by the Australian Government); and

(5) the NHMRC National Statement on Ethical Conduct in Human Research (2007) or its replacement, and any other relevant NHMRC publication or guideline that relates to clinical trials.

2.2 If any issue relating to the safety of Study Participants arises which requires a deviation from the Protocol, the Institution through the Principal Investigator may immediately make such a deviation without breaching any obligations under this Agreement. If there is a need for such a deviation the Institution must notify the Sponsor and the Reviewing HREC of the facts and circumstance causing the deviation as soon as is reasonably practical, but in any event no later than 5 working days after the change is implemented.

2.3 From time to time, the Sponsor may modify the Protocol by written notice to the Institution and Principal Investigator. Except where the modification is necessary to eliminate an immediate hazard to Study Participants or involves only logistical or administrative aspects of the trial, any modification may not be implemented before approval by the Reviewing HREC. If the parties determine that a modification will affect the cost of the Study, the parties shall amend Schedule 2 as agreed between them.

3. PRINCIPAL INVESTIGATOR

3.1 Role of Principal Investigator

The Institution has authorised the Principal Investigator as the person responsible on a day-to-day basis for the conduct of the Study. The Principal Investigator does not have authority on behalf of the Institution to amend this Agreement or the Protocol.

3.2 Liability for Principal Investigator

For the purpose of this Agreement only, and as between the Sponsor and the Institution only, the Institution agrees to be responsible for the acts and omissions of the Principal Investigator in relation to the conduct of the Study, to the extent that such responsibility would attach to the Institution in accordance with its obligations under this Agreement or under the common law on the basis that the Principal Investigator is acting as an employee of the Institution. Nothing in this clause or Agreement affects any pre-existing contractual or other arrangement which may be in place between the Institution and the Principal Investigator.

Protocol Number: IHLOSAPOC1 Site: Xxxxxx Health
Medicines Australia Standard CTRA 8 March 2017 (revised)	Page 5 of 38

3.3 Obligations and responsibilities

The Institution is responsible for ensuring that the Principal Investigator:

(1) thoroughly familiarises themselves with the appropriate use of the Investigational Product(s), as described in the Protocol, Investigator’s Brochure, information relating to the Investigational Product and any other information sources provided by the Sponsor;

(2) ensures written approval has been obtained to conduct the Study from the Reviewing HREC and the Institution prior to Study initiation. Written documentation of approval by the Reviewing HREC and the Institution must be provided to the Sponsor;

(3) conducts the Study according to the Protocol without changes, except as provided in clause 2.2 or 2.3, or as agreed to in writing by the Sponsor and the Institution and approved in accordance with clause 3.3(5);

(4) completes (and obtains completion from relevant Personnel) and returns to the Sponsor a statement of financial disclosure (an example that meets this requirement is Food and Drug Administration Form 3455 ‘Disclosure: Financial Interests and Arrangements of Clinical Investigators) before the commencement of the Study and as otherwise required, and consents to the disclosure of the completed form to overseas regulatory agencies, if required;

(5) ensures that any amendments to the Protocol are approved by the Reviewing HREC and Sponsor prior to implementation of the amendment;

(6) ensures that the Sponsor’s prior written consent is obtained to any advertisement in respect of the Study;

(7) provides the Sponsor with evidence of the Principal Investigator’s qualifications through a current curriculum vitae and/or other relevant documentation and a list of appropriately qualified persons to whom they have delegated significant Study-related duties, if required;

(8) uses their best endeavours to recruit the target number of Study Participants, within the recruitment period, specified in Schedule 1, provided that if the overall target number of Study Participants for the Study is reached, the Sponsor may direct the Institution to cease recruitment;

(9) is available when a clinical research representative of the Sponsor visits the Study Site, as mutually agreed prior to the visit, and is contactable by telephone or electronic mail as frequently as is reasonably required;

(10) notifies the Sponsor, the Institution and the Reviewing HREC of any Adverse Events (including Serious Adverse Events) that occur during the course of the Study in accordance with the Protocol and relevant ethical and regulatory guidelines, and, in the case of the Institution and the Reviewing HREC, with their policies and procedures;

(11) completes Case Report Forms within the agreed time period. The Principal Investigator will ensure that Study Participants’ identifying information are removed from all records being transferred to the Sponsor;

(12) provides regular written progress reports to the Sponsor in relation to the Study as required by the Protocol;

(13) completes and returns to the Sponsor as required any Study related materials within a reasonable time period;

Protocol Number: IHLOSAPOC1 Site: Xxxxxx Health
Medicines Australia Standard CTRA 8 March 2017 (revised)	Page 6 of 38

(14) is not subject to any obligations, either contractually or in any other way, which would unreasonably interfere with or prohibit the performance of work related to this Study; and

(15) ensures that informed consent to participate in the Study is obtained from each Study Participant prior to their enrolment in the Study and documented using an information and consent document which has been reviewed and approved by the Sponsor, the Institution and the Reviewing HREC.

4. INSTITUTION OBLIGATIONS AND RESPONSIBILITIES

4.1 If the Principal Investigator leaves the Institution or otherwise ceases to be available, then:

(1) the Institution must consult with the Sponsor and use reasonable endeavours to nominate as soon as practicable a replacement reasonably acceptable to both parties; and

(2) the Sponsor may require recruitment into the Study by the Institution to cease or move the Study to a different Study Site.

4.2 If the Principal Investigator fails to carry out those obligations specified in clauses 3.3(2), (3), (5), (8), (10), (11), (13) or (15), then the Institution must itself perform those obligations and rectify and make good any breach. The Institution will ensure that any Personnel who assist in the conduct of the Study are informed of and agree to abide by all terms of this Agreement relevant to the activities they perform.

4.3 The Institution warrants that, to the best of its knowledge, it and its affiliates and any other person involved in the conduct of the Study, including the Principal Investigator, are properly registered with appropriate professional registration bodies, have not been disqualified from practice or disbarred or banned from conducting clinical trials by any Regulatory Authority. Furthermore, the Institution shall notify the Sponsor as soon as practical after it becomes aware of any such disqualification, disbarment or ban.

4.4 The Institution will not engage in any conduct on the Sponsor’s behalf which is in violation of, or potentially in violation of, any applicable local or foreign laws or regulations.

4.5 The Institution warrants, represents and undertakes to the Sponsor that it has not offered, promised or paid, either directly or indirectly, any Benefit to a government official (including, but not limited to, a healthcare professional employed by a government-owned healthcare facility) to induce such government official to act in any way in connection with his or her official duties with respect to services performed under this Agreement or to otherwise obtain an improper advantage for the Institution or the Sponsor (Improper Payment), and has not received an Improper Payment, and will not offer, promise, pay, authorise or receive any Improper Payment in the future. For the purposes of the foregoing, Benefit includes but is not limited to money, financial or other advantage, travel expenses, entertainment, business or investment opportunities, charitable donations or any other thing of value.

4.6 The Institution must have adequate security measures to ensure the safety and integrity of the Investigational Product, Essential Documents and Study records and reports, Equipment and any Study related materials held or located at the Study Site.

4.7 Subject to clause 9, the Institution will allow regular monitoring visits in accordance with the GCP Guideline, access for the purposes of audit and as required by Regulatory Authorities or as specified in the Protocol and permit access to the Essential Documents (including original records), Study records, reports, other Study related materials and its Personnel as soon as is reasonably possible upon request by the Sponsor, Regulatory Authority, Reviewing HREC or any third party designated by the Sponsor. Any such access is to take place at times mutually agreed, during business hours and subject to such reasonable conditions relating to occupational health and safety, security, and confidentiality as the Institution may require.

Protocol Number: IHLOSAPOC1 Site: Xxxxxx Health
Medicines Australia Standard CTRA 8 March 2017 (revised)	Page 7 of 38

4.8 The Institution will make available adequate facilities, equipment and any other resource of the Institution reasonably required to safely follow the Protocol, provided that any amendments to the Protocol which take place after the execution of this Agreement and requiring any additional use of facilities, equipment, staff or resources, have been approved in writing by the Institution and the Reviewing HREC.

4.9 The Institution will have an adequate number of appropriately qualified Personnel for the foreseen duration of the Study and ensure that such Personnel are adequately informed about the Protocol, Investigational Product(s), and their Study- related duties and functions. The Personnel appointed by the Institution to assess Study Participants will attend an investigator meeting or a pre-study/initiation meeting, where appropriate.

4.10 The Institution must retain and preserve a copy of all Study Materials, including copies of signed consent forms, Case Report Forms, Protocol, information relating to the Investigational Product, correspondence and investigator files for at least 15 years from Study Completion and must ensure that no Study related materials are destroyed before the expiration of this time period without the written approval of the Sponsor. The Institution agrees to notify the Sponsor before destroying any Study Materials and agrees to retain the Study Materials for such longer period as reasonably required by the Sponsor at the Sponsor’s expense.

4.11 The Institution will ensure that the Study is subject to the continuing oversight of the Reviewing HREC throughout its conduct.

4.12 If the Institution is contacted by any Regulatory Authority in connection with the conduct of the Study, the Institution shall immediately notify the Sponsor, unless prevented from doing so by law.

4.13 The Institution will provide the Sponsor with all reasonable assistance and cooperation to rectify any matter raised by a Regulatory Authority or as the result of an audit of the Institution or Study Site. This includes execution of any documents reasonably requested by the Sponsor in connection with the requirements of a Regulatory Authority or the Sponsor as a result of such an audit. The cost will be borne by the Sponsor unless such rectification is due to the default of the Institution or the Principal Investigator.

4.14 The Institution shall obtain approval, in writing, from the Sponsor for any press statements or promotional statements regarding the Study or the Investigational Product(s) before the statements are released, unless the statement or disclosure is required by:

(1) law;

(2) any policy, guideline or direction of government or any government department or agency;

(3) any Regulatory Authority; or

(4) is, in the absolute discretion of the Institution, Minister for Health, Department of Health or any government official, reasonably necessary in the public interest or to protect the health and safety of any individual.

Protocol Number: IHLOSAPOC1 Site: Xxxxxx Health
Medicines Australia Standard CTRA 8 March 2017 (revised)	Page 8 of 38

5. SPONSOR OBLIGATIONS AND RESPONSIBILITIES

5.1 Prior to the Agreement being executed, the Sponsor must provide the Principal Investigator, and, through the Principal Investigator, the Institution and the Reviewing HREC, with all current and relevant information regarding the Investigational Product as reasonably required to justify the nature, scope and duration of the Study.

5.2 The Sponsor will implement and maintain quality assurance and quality control systems with written standard operating procedures to ensure that the Study can be conducted and data generated, documented, recorded and reported in compliance with all of the documents referred to in clause 2.1.

5.3 The Sponsor will designate appropriately qualified personnel to advise on Study- related medical questions or problems.

5.4 The Sponsor will monitor the application of the Investigational Product in other places (both within and outside Australia) and advise the Institution, through the Principal Investigator, and TGA of the cessation elsewhere of any relevant trial, or the withdrawal of the Investigational Product from any other market for safety reasons.

5.5 The Sponsor will notify the Institution of any Adverse Events (including Serious Adverse Events) that occur during the course of the Study (either at the Study Site or other study sites, including overseas sites) which may require alteration of the conduct of the Study, or which may affect the rights, interests, safety or well-being of Study Participants.

5.6 The Sponsor will cooperate with the Institution and/or the Reviewing HREC in investigating any Adverse Event (including Serious Adverse Event) arising out of or in connection with the Study.

5.7 To assist the Institution to comply with clause 8, the Sponsor will provide the Institution with adequate information and all necessary Investigational Product accountability forms.

5.8 The Sponsor will provide indemnity to the Institution and members of the Reviewing HREC against claims arising from the Study on the terms and conditions set out in the relevant Medicines Australia Form of Indemnity for Clinical Trials as set out in Schedule 3.

5.9 The Sponsor will comply with the Medicines Australia Guidelines for Compensation for Injury Resulting from Participation in a Company-sponsored Trial as specified in Schedule 5.

5.10 The Sponsor will maintain insurance with respect to its activities and indemnity obligations under this Agreement in accordance with Schedule 4. This insurance is to be evidenced by a certificate of insurance, as requested by the Institution from time to time.

6. PAYMENTS

6.1 In consideration of the Institution conducting the Study, the Sponsor will pay to the Institution as nominated in Schedule 2 in the manner and on the basis of the amounts and at the times set out in Schedule 2. The amounts set out in Schedule 2 do not include GST. At the time of payment, the Sponsor must pay to the Institution any amount of GST that the Institution is required to pay in addition to the amounts set out in Schedule 2, and in accordance with GST Law.

6.2 The Sponsor reserves the right to refuse to pay to the Institution payments specific to Study Participants entered into the Study who do not meet the entry criteria specified in the Protocol.

Protocol Number: IHLOSAPOC1 Site: Xxxxxx Health
Medicines Australia Standard CTRA 8 March 2017 (revised)	Page 9 of 38

6.3 If a Study Participant discontinues their participation in the Study or if the Study is terminated as a whole, only those costs incurred up until the date of discontinuation or termination, including costs of final visit and completion of all Case Report Forms, will be paid.

6.4 Payments will be made by the Sponsor upon either receipt of a valid tax invoice or a “Recipient Created Tax Invoice” issued by the Sponsor.

6.5 The Sponsor and the Institution each warrant that they are registered under GST Law. Tax invoices must identify supplies for which GST is payable.

6.6 The final payment will be made following Study Completion.

6.7 No part of any consideration paid hereunder is for the recommending or arranging for the referral of business or the ordering of items or services.

6.8 Neither this Agreement nor any consideration paid hereunder is contingent upon the Institution’s use or purchase of any of the Sponsor’s products.

7. PROVISION OF EQUIPMENT & SOFTWARE

7.1 The Sponsor will provide the Institution and Principal Investigator with the Equipment and Software at the Sponsor’s expense. Unless otherwise agreed by the parties in writing, the Equipment and Software will be used only by the Principal Investigator and Personnel involved in the conduct of the Study and only for the purposes of the Study.

7.2 If proper usage of the Equipment or Software requires training, the Institution agrees that:

(1) the Principal Investigator and Institution’s Personnel will make themselves available for training in using the Equipment and Software, at the Sponsor’s expense; and

(2) the Equipment and Software will only be used as described in written directions provided by the Sponsor.

7.3 The Equipment will be at the risk of the Sponsor, but the Institution will take reasonable care in the use and secure storage of the same and the Institution is responsible for damage caused to or by the Equipment by the negligence of its Personnel.

7.4 At the completion of the Study or at the Sponsor’s request, the Institution will, unless otherwise specified, return to Sponsor, at the Sponsor’s expense, the Equipment and Software and all related training materials and documentation.

7.5 The Sponsor will cooperate with the Institution in maintaining, at the Sponsor’s expense, the Equipment in good working order, and ensuring that it is in a safe condition and compliant with the requirements of the relevant licensing and safety authorities at all times.

7.6 The Institution will not copy the Software unless specifically authorised by the Sponsor.

8. INVESTIGATIONAL PRODUCT

8.1 The Institution must:

(1) ensure that all Investigational Product made available by the Sponsor is used strictly according to the Protocol and are not used for any other purposes, unless agreed in writing by the Sponsor;

(2) provide a written explanation accounting for any missing Investigational Product;

Protocol Number: IHLOSAPOC1 Site: Xxxxxx Health
Medicines Australia Standard CTRA 8 March 2017 (revised)	Page 10 of 38

(3) not charge a Study Participant or third-party payer for Investigational Product or for any services reimbursed by the Sponsor under this Agreement;

(4) keep all Investigational Product under appropriate storage conditions (including any conditions specified in the Protocol) and in a secured area accessible only to authorised Personnel; and

(5) ensure that complete and current records are maintained for all received, dispensed and returned Investigational Product.

8.2 The Sponsor will supply the Principal Investigator with such quantities of the Investigational Product as will be required for the purpose of the Study. All supplied Investigational Product will be packaged in safe and appropriately labelled containers. The Sponsor will at all times remain the sole owner of the Investigational Product.

8.3 On termination of this Agreement, the Institution must promptly return any unused Investigational Product to the Sponsor, or, if requested by the Sponsor, destroy it and provide evidence of such destruction.

9. CONFIDENTIALITY

9.1 Subject to clause 9.2, each party must not, and must ensure their Personnel do not, use or disclose any Confidential Information of the other party, other than where and only to the extent that such use or disclosure is necessary for the performance of the Study, the exercise of its rights or the performance of its obligations under this Agreement.

9.2 The Institution may use or disclose Sponsor Confidential Information in any of the following circumstances:

(1) for the purposes of complying with the Institution’s internal complaint procedures, accident reporting procedures, quality assurance activities, disciplinary procedures or any applicable policy in relation to patient safety, Adverse Events and/or reportable incidents;

(2) for the purposes of disclosing any material risks, identified during the Study or subsequent to it, to Study Participants, Principal Investigators, medical practitioners administering treatment to Study Participants, Reviewing HRECs and Regulatory Authorities;

(3) for the purposes of complying with the requirements of any Regulatory Authority;

(4) to enable the Reviewing HREC to monitor the Study;

(5) where the Sponsor consents in writing to the disclosure;

(6) as part of a publication issued under the provisions of clause 11;

(7) where release of the Confidential Information is required by law, with notice as soon as reasonably practical to the Sponsor, and subject to the Institution upon request providing reasonable assistance to enable the Sponsor to obtain a protective order or other remedy to resist disclosure or ensure confidential treatment for any required disclosure;

(8) for the purposes of the Institution seeking legal advice; or

(9) disclosure to the Institution’s insurer.

9.3 Where Confidential Information is disclosed in accordance with clause 9.2 (1), (4), (8) or (9) the Confidential Information must only be used in connection with the legitimate purposes of the Institution, and only disclosed to those who have a need to know it for such purposes and are obligated to keep the information confidential.

Protocol Number: IHLOSAPOC1 Site: Xxxxxx Health
Medicines Australia Standard CTRA 8 March 2017 (revised)	Page 11 of 38

9.4 The Sponsor may disclose Institution Confidential Information to its lawyers for the purposes of obtaining legal advice or to its Affiliates but only on a needs to know and confidential basis. The Sponsor may disclose Institution Confidential Information if required by law, with notice as soon as reasonably practical to the Institution, and subject to the Sponsor upon request providing reasonable assistance to enable the Institution to obtain a protective order or other remedy to resist disclosure or ensure confidential treatment for any required disclosure.

9.5 The parties are responsible for ensuring that their Personnel are aware of the obligations in respect of Confidential Information in this clause 9 and are bound in similar terms to keep such information confidential.

9.6 Information will not be Confidential Information and subject to the provisions of this clause 9 where:

(1) the information has been independently received from a third party who is free to disclose it;

(2) the information is in or has entered the public domain other than as a result of a breach of this Agreement;

(3) the party already knew the information, the prior knowledge of which it can document by prior written records; or

(4) the party independently develops, discovers or arrives at the information without use, reference to, or reliance upon, the Confidential Information.

10. PRIVACY

10.1 Each party must ensure that any Personal Information of Study Participants or Personnel it obtains or holds as a result of the conduct of the Study is collected, stored, used and disclosed by it in accordance with the Relevant Privacy Laws.

10.2 Each party will promptly report to the other party any unauthorised access to, use or disclosure of Personal Information of Study Participants (“Incident”) of which it becomes aware, and will work with the other party to take reasonable steps to remedy the Incident.

11. PUBLICATIONS

11.1 The Institution, Principal Investigator and other investigators (each a Discloser) involved in the Study have the right to Publish the methods, results of, and conclusions from, the Study, subject to this clause and in accordance with copyright law.

11.2 If the Study is a Multi-centre Study, then the Institution agrees that no Publication of the Study results may be made until Publication of the results of the Multi-centre Study or 2 years after Study Completion, whichever is the sooner. The further provisions of this clause still apply to any such Publication.

11.3 The Institution must ensure that the Discloser gives a copy of any proposed Publication drafted by them and/or other Personnel involved in the conduct of the Study to the Sponsor at least 40 days before forwarding it to any person that is not bound by the confidentiality obligations set out in clause 9.

11.4 The Sponsor may, within that 40-day period do any one or more of the following:

(1) provide comments on the proposed Publication to the Institution, in which case the Institution must consider such comments but will not be bound to follow them;

(2) request delay of Publication for no more than 120 days to allow the Sponsor to file patent applications or take other measures to preserve or secure its Intellectual Property, in which case the Institution must abide by that request; or

Protocol Number: IHLOSAPOC1 Site: Xxxxxx Health
Medicines Australia Standard CTRA 8 March 2017 (revised)	Page 12 of 38

(3) request that the Discloser remove specified Confidential Information (other than the results of the Study) from the Publication, in which case the Institution must remove such specified Confidential Information as is reasonably required to protect the Intellectual Property of the Sponsor.

11.5 If the Institution has not received any comments from the Sponsor on the proposed Publication within 40 days of giving a copy to the Sponsor under clause 11.3, the Discloser may proceed to make the Publication.

11.6 Where the Sponsor intends to Publish the method, results or conclusions from the Study, any person named as an author on that Publication will be given a reasonable opportunity to review the Publication. Any person acknowledged as an investigator of the Study in the Publication will be given a reasonable opportunity to request the removal of his or her name from the Publication and the Sponsor shall comply with any such request.

11.7 In all Publications the Sponsor’s support of the Study shall be acknowledged.

11.8 The Sponsor may Publish a summary of the Study Results and conclusions on the Sponsor’s on-line Clinical Trial Register before or after Publication by another method.

11.9 The Sponsor may freely use, copy and disseminate any manuscript following its Publication in a journal without further obligation to the Institution or Discloser.

11.10 The Sponsor may only use the Institution’s and Investigators’ names:

(1) in relation to the publication of the Study on reputable clinical trials registers and websites in accordance with the CONSORT 2010 Statement;

(2) in Study publications and communications including Study newsletters made to the Institution and any other person which is subject to substantially the same confidentiality obligations as those set out in clause 9, in relation to performance of the Study; or

(3) in Study publications and communications made to any third party not subject to the confidentiality obligations set out in clause 9, with the Institution’s prior written consent.

12. STUDY MATERIALS AND INTELLECTUAL PROPERTY

12.1 The Sponsor grants to the Institution and its Personnel the right to use the Background IP of the Sponsor and the Study Materials as required to carry out the Study and perform this Agreement. Except for this right, neither the Institution nor any of its Personnel acquires any right or interest in any Intellectual Property provided by or on behalf of the Sponsor.

12.2 In order to carry out the Study, the Institution may use Intellectual Property which is part of the Institution’s Background IP. Any such Background IP remains the sole property of the Institution. The Institution grants to the Sponsor a non-exclusive, perpetual, royalty free licence to use (including the right to sub-licence) the Institution’s Background IP solely for the purpose of the commercialisation of the Study Materials.

12.3 Subject to clause 12.2, all Intellectual Property in the Study Materials will vest automatically upon its creation in the Sponsor, and the Institution presently assigns to the Sponsor all Intellectual Property rights contained in the Study Materials. The Institution agrees to execute or procure the execution by its Personnel of any documents reasonably necessary to give effect to this assignment, at the Sponsor’s expense.

12.4 The Institution must promptly disclose and communicate in writing to the Sponsor full particulars of any Intellectual Property that the Institution or Principal Investigator make, discover or conceive in the course of the Study that is directly related to the Study Materials.

Protocol Number: IHLOSAPOC1 Site: Xxxxxx Health
Medicines Australia Standard CTRA 8 March 2017 (revised)	Page 13 of 38

13. TERM AND TERMINATION

13.1 This Agreement commences from the date specified on the first page of this Agreement, or if such date is not included on the date this Agreement is last signed by either the Sponsor or Institution. In the ordinary course of events this Agreement terminates when the Sponsor makes its final payment to the Institution.

13.2 A party may terminate this Agreement with 30 days prior written notice or such shorter time period as is reasonably required in the circumstances if the other party:

(1) is in breach of any obligations under the Agreement or the Protocol (including without just cause to meet a timeframe) and fails to remedy such breach where it is capable of remedy within 30 days of a written notice from the terminating party specifying the breach and requiring its remedy;

(2) is declared insolvent or has an administrator or receiver appointed over all or any part of its assets or ceases or threatens to cease to carry on its business; or

(3) assigns this Agreement to a person considered unsuitable to perform the Agreement as set out in clause 19.3.

13.3 In addition to clause 13.2, a party may terminate this Agreement immediately by written notice to the other party if it believes on reasonable grounds that:

(1) continuing the Study poses an unacceptable risk to the rights, interests, safety or well-being of Study Participants; and

(2) terminating this Agreement is the most appropriate way to respond to that risk.

13.4 The Sponsor may terminate this Agreement if the Institution breaches clause 4.5 or if the Sponsor learns that the Institution is making, or has made, Improper Payments (within the meaning of clause 4.5) to government officials with respect to services performed on behalf of the Sponsor or any other company. Further, in the event of such termination, the Institution will not be entitled to any further payment or compensation.

13.5 The Sponsor may terminate this Agreement with 30 days prior written notice to the Institution. In the event of such early termination, the Sponsor will pay the reasonable costs of the Institution relating to the Study calculated in accordance with Schedule 2.

13.6 In the event of termination, the Institution must promptly initiate all appropriate action to close the Study and, subject to any applicable retention requirements imposed by law, return to the Sponsor (or destroy if requested by the Sponsor, and provide evidence of such destruction) any completed Case Report Forms and other materials received from the Sponsor before Study Completion.

13.7 In the event of termination the Sponsor must take all appropriate action to close out the Study Site in a timely manner.

13.8 In the event of early termination, the Sponsor will cooperate with the Institution to ensure that Study Participants who may be affected by termination receive adequate medical care. This may include the provision of Investigational Product in certain circumstances at the Sponsor’s expense.

13.9 The following provisions survive termination of this Agreement, clauses 1, 3.2, 3.3(11), 4.6, 4.7, 4.10, 4.12, 4.13, 4.14, 5.8, 5.9, 5.10, 6.1, 8.3, 9, 10, 11, 12, 13.5, 13.6, 13.7, 13.8, 13.9, 14, 15, 16, 18 and 20.

Protocol Number: IHLOSAPOC1 Site: Xxxxxx Health
Medicines Australia Standard CTRA 8 March 2017 (revised)	Page 14 of 38

14. DISPUTES

14.1 No party may commence legal proceedings against another in respect of a dispute arising in relation to this Agreement (except for urgent interlocutory relief) unless the parties have complied with this clause and that party has first notified the other party in writing of the dispute and has used all reasonable endeavours to resolve the dispute with the other party within 28 days of the giving of that notice (Initial Period).

14.2 If the dispute is not resolved within the Initial Period, then the dispute shall be referred within a further 28 days to the Australian Disputes Centre for mediation or any other agreed venue which conducts mediation. The parties will by agreement appoint a mediator to mediate the dispute in this forum. If the parties cannot agree to a mediator within 14 days of the end of the Initial Period, then the mediator will be nominated by the then current President of the Law Society of the State or Territory in which the Institution is located. Any documents produced for the mediation are to be kept confidential and cannot be used except for the purpose of settling the dispute.

14.3 Each party must bear its own costs of resolving a dispute under this clause, and unless the parties otherwise agree, the parties to the dispute must bear equally the costs of the mediator.

14.4 In the event that the dispute is not settled at mediation within 28 days (or such other period as the parties agree in writing) after the appointment of the mediator, then the parties are free to pursue any other procedures available at law for the resolution of the dispute.

15. APPLICABLE LAW

This Agreement will be governed by, and construed in accordance with, the law for the time being in force in the State or Territory in which the Institution is located and the parties submit to the jurisdiction of that State or Territory and courts entitled to hear appeals from those courts.

16. NOTICES

16.1 A notice, consent, approval or other communication (each a notice) under this Agreement must be:

(1) delivered to the party’s address; or

(2) sent by pre-paid mail to the party’s address; or

(3) transmitted by facsimile to the party’s address.

16.2 A notice given by a party in accordance with this clause is treated as having been given and received:

(1) if delivered to a person’s address, on the day of delivery if a business day, otherwise on the next business day; or

(2) if sent by pre-paid mail, on the third business day after posting; or

(3) if transmitted by facsimile to a person’s address and a correct and complete transmission report is received, on the day of transmission if a business day, otherwise on the next business day.

16.3 The addresses of the parties for the purposes of giving any notice are set out on the front page of this Agreement.

17. WAIVER

17.1 No right under this Agreement is waived or deemed to be waived except by notice in writing signed by the party waiving the right. A waiver by any party in respect of any breach of a condition or provision of this Agreement will not be deemed to be a waiver in respect of any other breach.

Protocol Number: IHLOSAPOC1 Site: Xxxxxx Health
Medicines Australia Standard CTRA 8 March 2017 (revised)	Page 15 of 38

17.2 Failure or delay by any party to enforce any provision of this Agreement will not be deemed to be a waiver by that party of any right in respect of any other such breach.

18. VARIATIONS

No variations of this Agreement are legally binding on any party unless evidenced in writing signed by all parties.

19. ASSIGNMENT

19.1 Subject to clause 19.2, a party (the Assigning Party) may assign its rights or novate its rights and obligations under this Agreement after obtaining the prior written consent of the other party (the Other Party).

19.2 The Assigning Party’s request for the Other Party’s consent to an assignment or novation of this Agreement must include:

(1) the name and the address of the proposed assignee or novatee;

(2) a copy of the proposed deed of assignment or novation; and

(3) such other information as the Other Party reasonably requires.

19.3 Provided the proposed novatee is an Australian entity, the Other Party must give its consent promptly if:

(1) the Assigning Party provides evidence that ought reasonably satisfy the Other Party that the proposed novatee is financially secure and has the ability to carry out the Assigning Party’s obligations under this Agreement;

(2) the proposed novatee signs a deed or agreement in which it covenants with the Other Party and the Assigning Party to perform the obligations of the Assigning Party under this Agreement;

(3) the Assigning Party is not in breach of this Agreement; and

(4) the Assigning Party pays the Other Party’s reasonable costs of giving its consent.

19.4 The Assigning Party remains liable for its obligations under this Agreement even if it assigns its rights pursuant to clause 19.1.

20. SUBCONTRACTING

20.1 The Sponsor may subcontract any of its obligations under this Agreement, save for the obligations set out in clauses 5.8, 5.9 and 5.10. The Sponsor remains responsible for all subcontracted obligations and is liable for all acts and omissions of any subcontractor as if they were the Sponsor’s acts and omissions. In the event that the Sponsor subcontracts with another party to perform any of the Sponsor’s obligations under this Agreement, the Sponsor is bound by and will observe its obligations under clause 9.1 in its dealings with the subcontractor.

20.2 No subcontractor will have any rights under this Agreement against the Institution or be entitled to receive any payment from the Institution.

20.3 For the purpose of this Agreement only, and as between the Sponsor and the Institution only, where the Institution subcontracts any of its obligations under this Agreement, the Institution remains responsible for all subcontracted obligations and is liable for all acts and omissions of any subcontractor as if they were the Institution’s acts and omissions.

Protocol Number: IHLOSAPOC1 Site: Xxxxxx Health
Medicines Australia Standard CTRA 8 March 2017 (revised)	Page 16 of 38

21. ENTIRE AGREEMENT

This Agreement constitutes the entire agreement between the parties in relation to the Study and supersedes all prior representations, agreements, statements and understandings, whether verbal or in writing in relation to the Study.

22. FURTHER DOCUMENTS

Each party will do anything (including executing any document), and will ensure that its Personnel do anything (including executing any document), that the other party may reasonably require to give full effect to this Agreement.

23. SEVERANCE

If any part of this Agreement is prohibited, void, voidable, illegal or unenforceable, then that part is severed from this Agreement but without affecting the continued operation of this Agreement.

24. RELATIONSHIP OF THE PARTIES

Nothing in this Agreement creates a relationship of employer and employee, principal and agent, joint venture or partnership between the parties and no party will hold itself out as an agent for another.

25. FORCE MAJEURE

If any party is delayed or prevented from the performance of any act required under this Agreement by reason of any act of God, act of nature, including any epidemic or outbreak of pandemic disease, fire, act of government or state, war, civil commotion, insurrection, embargo, prevention from or hindrance in obtaining raw material, energy or other supplies, labour disputes of whatever nature or whatever reason beyond the control of the party (a Force Majeure Event), the affected party shall promptly notify the other party in writing, giving details of the Force Majeure Event, the acts affected by the Force Majeure Event and the extent to which they are affected, and performance of such acts shall be excused for the period of such event provided that if such interference lasts for any period in excess of 30 days either party may, by written notice to the other, terminate this Agreement.

26. COUNTERPARTS

This Agreement may be executed in any number of counterparts. All counterparts taken together are deemed to constitute one and the same Agreement.

27. CONFLICT

In the event of any inconsistency between this Agreement and the Protocol, this Agreement prevails.

Protocol Number: IHLOSAPOC1 Site: Xxxxxx Health
Medicines Australia Standard CTRA 8 March 2017 (revised)	Page 17 of 38

In witness hereof, the parties have caused this Agreement to be executed as of respective dates written below.

Signed on behalf of the Sponsor

Signed:

Name:

Position: 

Date:

Signed on behalf of the Institution  

Signed:

Name:

Position: 

Date:

The Principal Investigator acknowledges this Agreement and understands the obligations it imposes.

Acknowledged by the Principal Investigator  

Signed:

Name:

Position: 

Date:

Protocol Number: IHLOSAPOC1 Site: Xxxxxx Health
Medicines Australia Standard CTRA 8 March 2017 (revised)	Page 18 of 38

Schedule 1
Key Information
Study Name:	Dose finding crossover trial investigating the effect of dronabinol combined with acetazolamide on Apnoea Hypopnea Index (AHi) in adults with obstructive sleep apnoea (OSA)
Study Site/s:	The Xxxxxx Hospital

Target number of Study Participants:	Minimum: 12
	Maximum: 12
Recruitment Period:	Start: 07/SEP/2020                                  End: 01/MAR/2021
Principal Investigator Name:	Xxxxxxxxx Xxxxxxx X’Xxxxx
Address:	Department of Neurosciences, 4th Floor, Centre Block
	The Xxxxxx Hospital, 00 Xxxxxxxxxx Xxxx, Xxxxxxxxx
	Xxxxx: Xxxxxxxx, Xxxxxxxxx                                  P/code: 3004

Reviewing HREC:	Xxxxxx Health Human Research Ethics Committee
Equipment provided by Sponsor:	NIL
Software provided by Sponsor:	NIL
Investigational Product:	Dronabinol
	Acetazolamide

Protocol Number: IHLOSAPOC1 Site: Xxxxxx Health
Medicines Australia Standard CTRA 8 March 2017 (revised)	Page 19 of 38

Schedule 2

Payments

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]	[***]
[***]	[***]

Protocol Number: IHLOSAPOC1 Site: Xxxxxx Health
Medicines Australia Standard CTRA 8 March 2017 (revised)	Page 20 of 38

Payments

Study Site Activities

Activity	[***]
The Site Start Up Fee of will be paid upon the completion of the Site Initiation Visit.	[***]
Study Site Administration Fee will be paid quarterly, starting from the Site Initiation Visit or Pre-screening (whichever occurs first), until the Close out Visit.	[***]
The Site Training Fee, a one-off fee, will be payable on the completion of all training required for the study conduct, including eCRF training. This payment is per system trained on per investigator and co-ordinator.	[***]
Human Research Ethics Committee (HREC) Review Fee, a one-time fee, for the review of the initial submission package for the trial, will be payable upon receipt of invoice	[***]
Pre-Screening Fee The Pre-Screening Fee is paid for the pre-screening activities performed by the Institution to identity potential Participants by assessing medical records and databases. Pre-screening activities will be documented on a log to support pre-screening tasks. This fee is paid annually from the first anniversary of the SIV.	[***]
Amendment Preparation Fee - Major This fee will be paid for the preparation of a major Protocol amendment or Participant Information and Consent Form (PICF) for RGO review.	[***]
Amendment Preparation Fee - Minor This fee will be paid for the preparation of amendments relating to Investigator Brochures (IBs), safety documents, participant facing materials, advertising or for RGO review.	[***]
Amendment Preparation Fee - Major, within one month of RGO approval This fee will be paid if a Protocol and/or PICF is prepared and submitted to the Xxxxxx RGO within and up to one calendar month after initial RGO approval.	[***]

Protocol Number: IHLOSAPOC1 Site: Xxxxxx Health
Medicines Australia Standard CTRA 8 March 2017 (revised)	Page 21 of 38

Amendment Preparation Fee - Minor, within one month of RGO approval This fee will be paid if an IBs, safety document, participant facing material, advertising or changes to site staff become available and are submitted to the Xxxxxx RGO within and up to one calendar month after initial RGO approval.	[***]
Study Close Out A one-time Close Out Fee will be paid upon completion and approval by the Sponsor of any outstanding data documentation (eCRFs and data clarifications issued) and regulatory documentation.	[***]
Archiving Fee The one-time Archiving Fee will be paid for the archiving of 2 boxes as per ICH GCP and local requirements. This Fee also includes electronic scanning and secure destruction at the end of the archiving period.	[***]
Archiving Fee - Additional Box The Archiving Fee -Additional Box Fee will be paid for any boxes in addition to the original 2 boxes. Prior Sponsor approval is required.	[***]
Archiving - Box Retrieval The Archiving - Box Retrieval Fee will be paid if a storage box requires retrieval from the archiving location.	[***]
Audit Fee The Audit Fee will be paid for the preparation, attendance and follow up of an Audit. This fee is capped at three (3) business days. This fee is not payable when the Audit is “for cause”.	[***]
Participant transport Allowance Participant transport allowance will be paid, up to a maximum of $150 per day during each treatment period throughout the study. This may be reimbursed on presentation of receipts to support the costs of transportation or granted as taxi vouchers. Receipts for reimbursements and taxi vouchers must include date of travel, amount per trip.	[***]
Participant Sleep Study Allowance Participants will be reimbursed $25 per hour up to a maximum of 8 hours for their time spent at site performing each sleep study.	[***]
Breakfast Allowance Each participant, that completes a sleep study will also be provided with a breakfast allowance, up to a maximum of $25 to be purchased at the hospital.	[***]

Protocol Number: IHLOSAPOC1 Site: Xxxxxx Health
Medicines Australia Standard CTRA 8 March 2017 (revised)	Page 22 of 38

Pharmacy and Pathology Activities

Activity	Cost ($AUD) All fees exclude GST
A Pharmacy Setup and Study Establishment Fee will be payable upon the attendance and completion of the Site Initiation Visit. This fee will be payable upon invoice.	[***]
A Pharmacy Annual Fee, will be payable for the management and administration of the study. This fee will be payable upon invoice.	[***]
A Pharmacy storage of Investigational Product Fee will be payable for the storage of the IP in a refrigerated safe, suitable for refrigerated Schedule 8 licenced products. This fee will be payable upon invoice.	[***]
A Dispensing of Investigational Product Fee, which includes accountability, will be payable for every dispensing of IP for participants and post accountability visit and with the monitoring fee	[***]
An Investigational Product Accountability Fee is incorporated into the dispensing fee.	[***]
An Investigational Product Destruction Fee will be payable should the sponsor request that IP be destroyed on-site, according to hospital guidelines. This fee will be payable upon invoice.	[***]
A Remote Monitoring Fee will be payable for each hour the Clinical Research Associate requires for the purposes of IP accountability, should this service be requested. The IP accountability visit will be scheduled in advance and with the clinical trials pharmacist. This fee will be payable upon invoice. Note: there is no additional charge for on-site monitoring.	[***]
After Hours Call Back Fee The After Hours Call Back Fee will be paid when IP requires preparation and dispensation outside the hours of 8am - 5pm due to unforeseen circumstances. An initial amount of Six Hundred and Ninety Australian Dollars (690 AUD) will be paid for the first three (3) hours. After the first three (3) hours, this fee will be charged at the rate of One Hundred and Fifty-Five Australian Dollars (155 AUD) per hour.	[***]

Protocol Number: IHLOSAPOC1 Site: Xxxxxx Health
Medicines Australia Standard CTRA 8 March 2017 (revised)	Page 23 of 38

A Pharmacy Close Out Fee, a one-time fee, will be payable upon the final close out visit, after all remaining or used Investigational Product as either been returned to the sponsor or destroyed upon written notification from the sponsor, and all pharmacy files have been returned to the site for archiving. This fee will be payable upon invoice, no later than 30 days post close out visit.	[***]
Pathology Activities	[***]
A Protocol review and SSA completion Fee, a one-time fee, will be payable upon completion of the Site Initiation Visit and upon invoice.	[***]
An Establishment Fee, a one-time fee for the establishment of the trial, upon Site Initiation Visit and payable upon receipt of an invoice.	[***]
Test or service fee	[***]
Standard HAEM panel	[***]
Standard BIOCHEMISTRY panel	[***]
Urinalysis	[***]
Urine pregnancy test	[***]
Specimen shipping, per shipment	[***]
Health Information Services
Retrieval fee for paper medical records (per volume) from onsite storage	[***]
Retrieval fee for paper medical records (per volume) from external storage	[***]
Registration Fee, per participant	[***]
Permanent retention (per volume) of medical records for research	[***]
ICD10 Diagnosis database participant information search (per search)	[***]

1. General Terms. Payee will be compensated as outlined on the attached study budget (“Budget”) for Study Participants properly enrolled in the Study. This amount constitutes the full compensation for the work to be completed by the Institution and Principal Investigator, including all work and care specified in the Protocol for the Study, along with all overhead and administrative services. No compensation will be available for Study Participants enrolled in the Study in violation of the Protocol.

As indicated below (Point 8), the payee of these funds is Monash University (“Payee”), which is a payment administrator and is not party to this Agreement. Organisation’s or Local Sponsor’s only payment obligation under this Agreement is to pay Monash University. Administration of funding by Payee on behalf of Institution is governed by a separate agreement between those entities. Institution releases Organisation and Local

Protocol Number: IHLOSAPOC1 Site: Xxxxxx Health
Medicines Australia Standard CTRA 8 March 2017 (revised)	Page 24 of 38

2. Payment Tenns. Payments for each Study Participant will be made in Australian Dollars (AUD) quarterly and based on CRF data entered by Institution and/or Principal Investigator supporting enrolled Study Participant visitation. Payments will be made for completed visits and treatment related costs in accordance with the Budget, unless otherwise noted in the Agreement. For each payment, including any Screen Failures (as defined below) that may be payable under the terms of this Agreement, Payee will be paid the total amount earned, less 10%, for the Final Payment (hereinafter defined). Monitoring will occur approximately every 8 weeks based on Study Site enrolment and completion of data entry. All queries must be resolved within five (5) business days of receipt by Institution and/or Principal Investigator any time during the Study. Payee must submit any final valid tax invoices within thirty (30) calendar days after the close-out visit of the Study at the Institution. Any invoices received thereafter may not be paid. Payee will have sixty (60) calendar days after the date of the close-out visit of the Study at the Institution to dispute any payment discrepancies or missing payments.

3. Non-Procedural Costs. Payee will be paid for additional non-procedural costs that are pre-approved by Organisation/Local Sponsor as set forth in the Budget. To request payment for such costs, Payee will remit valid tax invoice to Local Sponsor or its designee with documentation and receipts substantiating agreed-upon pass-through expenses. Any non - procedural pass-through expenses will be invoiced only in the amount actually incurred with no xxxx-up, up to the maximum amounts shown in the Budget.

4. Final Payment. At the conclusion of the Study, all CRFs and Study-related documents will be promptly made available for Organisation/Local Sponsor review. The final payment (“Final Payment”) will be paid once: all CRFs have been completed and received; data queries have been satisfied; all Investigational Product is returned; and all close out issues are resolved and procedures completed, including final HREC and/or Regulatory Authority notification, if applicable. All queries must be resolved within five (5) business days of receipt by Institution and/or Principal Investigator. Local Sponsor or its designee will perform final reconciliation of all payments made to date against total amount due and will promptly pay Payee amounts remaining unpaid, if any. Payee will promptly reimburse Local Sponsor any unearned or overpaid amounts previously paid to Payee within thirty (30) calendar days of notification by Local Sponsor or designee.

5. Taxes.

1) Payments shown in the Budget do not include GST. If the Payee is GST registered, and if GST is required under the GST Law, GST should be added and shown on the invoice by the Payee at the applicable GST rate, along with Payee’s GST registration number.

2) Payee acknowledges and agrees that it is solely responsible for the payment of any and all contributions and taxes imposed by any applicable authority with respect to or measured by compensation paid to Payee under this Agreement. Local Sponsor/designee will not be responsible for the withholding or payment of any such required contributions or taxes. Payee accepts full responsibility for reporting all payments received, under this agreement, to the relevant taxation authorities as required by local regulations.

6. Screen Failures. A Screen Failure is a consented Study Participant who fails to meet the screening visit criteria and is thus not eligible for enrolment into the Study (“Screen Failure”). Screen Failures will be reimbursed, if at all, as outlined in the Budget.

7. Necessary Procedures. Payee will be reimbursed for valid necessary visits and procedures not covered under the Budget. Payment for any necessary procedure due to Study Participant safety will be reimbursed at the agreed upon unit cost in the Budget, if available, or if there is no such unit cost in the Budget, Payee will be compensated based on actual costs incurred by Institution and Principal Investigator and will require a separate valid tax invoice with documentation for the medical necessity of the procedure. Where practicable, Local Sponsor or Organisation’s prior written consent will be obtained, unless it will compromise the integrity of the Study or affect Study Participant safety, in which case Local Sponsor or Organisation will be notified as soon as practicable after the fact.

Protocol Number: IHLOSAPOC1 Site: Xxxxxx Health
Medicines Australia Standard CTRA 8 March 2017 (revised)	Page 25 of 38

8. Payee. The Institution has authorised Monash University to be responsible for financial administration of the Study funds as its Payee. The Parties acknowledge that Payee is authorised to receive and administer all Study payments on behalf of the Institution and that the Sponsor’s only payment obligation under this Agreement is to the Payee. Institution releases Sponsor from any obligation or liability related to handling or disbursement of the funds by Payee.

9. The payments will be made to the following Payee and address:

Payee Name	Monash University
Payee Address	000 Xxxxxxxxxx Xxxx, Xxxxxxxx, Xxxxxxxx, Xxxxxxxxx
Australian Business Number	12 377 614 012
Recipient Address	Receivables and Revenue Accounting Xxxxx 0, 000 Xxxxxxxxxx Xxxx Xxxxxxxx, XXX, 0000
Recipient Phone Number	[***]
Recipient Email	[***]
Payee Bank Account Details:
Bank Name	Westpac Banking Corporation
Bank Address	Campus Centre, Clayton Campus, Monash University, Xxxxxxxx, 0000, Xxxxxxxxx
Account Name	Monash University General Account
BSB Number	[***]
Bank Account Number	[***]
SWIFT Code	[***]
IBAN	[***]
Duns Number	[***]

Notification of all payments by EFT/direct credit made under this Agreement will be communicated to the Executive Officer at the following address:

Monash: M51007 - Department of Neuroscience/Van Cleef/Roet Centre for Nervous Diseases - Research

XX Xxx 000 Xxxxxxx 0000

The Xxxxxx Hospital, 00 Xxxxxxxxxx Xx, Xxx 0000
Telephone No.: +[***]

E-Mail Address: [***]

Protocol Number: IHLOSAPOC1 Site: Xxxxxx Health
Medicines Australia Standard CTRA 8 March 2017 (revised)	Page 26 of 38

The notification of all payments made under this Agreement will be accompanied with documentation of the calculation of each payment. The documentation will specify:

● The Human Research Ethics Committee (HREC) project number

● The Principal Investigator’s name;

● What the payment is being made for:

● The number of participants who have completed particular milestones; and

● Detail of any partial payments, or any other information relevant to the calculation of the payment by Neuroscience Trials Australia.

* Copies of all payment notices will be sent to the attention of the Management Accountant - Research at the following address:

Monash: M51007 - Department of Neuroscience/Van Cleef/Roet Centre for Nervous Diseases - Research

XX Xxx 000 Xxxxxxx 0000

00 Xxxxxxxxxx Xx, Xxx 0000

Telephone No.: [***]

Facsimile No.: [***]

E-Mail Address: [***]

10. Invoices. All invoices must be issued and forwarded to the following as instructed:

Email:

Sponsor Address;
lncannex Healthcare Ltd

0 Xxx Xxxxxx, Xxxxxxx Xxxxxxx, XXX 0000
Xxxxxxxxx

ABN 93 096 635 246

All payment related queries may be directed to:

Email: [***]

Each invoice must contain: (1) Organisation’s name, (2) Protocol number, (3) Study code, (1) Principal Investigator’s name, (5) a summary of the reimbursement to be made in compliance with the Budget, and (6) if the Payee is GST registered, the Australian Business Number (ABN).

Payee will not receive any payments for pass through expenses whereby Payee has failed to produce actual copy invoices or other documentation clearly substantiating that the expenditures were actual, reasonable, and verifiable in the amount submitted for compensation.

Suggested High Level Subject matter

Protocol Number: IHLOSAPOC1 Site: Xxxxxx Health
Medicines Australia Standard CTRA 8 March 2017 (revised)	Page 27 of 38

Schedule 3

Form of Indemnity for Clinical Trials

The Sponsor agrees to execute and deliver to the Institution, as necessary, an indemnity in the form of the Medicines Australia Standard Form of Indemnity for Clinical Trials without amendment.

Indemnity for Clinical Trials; HREC Review Only and Standard Forms on following pages.

Protocol Number: IHLOSAPOC1 Site: Xxxxxx Health
Medicines Australia Standard CTRA 8 March 2017 (revised)	Page 28 of 38

MEDICINES AUSTRALIA FORM OF INDEMNITY FOR CLINICAL TRIALS

HREC REVIEW ONLY

For use where the Indemnified Party Is providing ethical review for a multicentre clinical Study where the ethical review will be adopted by hospitals, institutions or sites that are independent from the Indemnified Party, OR as a Reviewing HREC for a single centre study at a hospital or institution that is independent from the Indemnified Party.

NOTE there is a different Form of Indemnity for use where the Indemnified Pany is providing premises for the conduct of the Study and HREC Review, or is providing premises only [The STANDARD Form of Indemnity]

This Form has been developed by Medicinos Australia and is an adaptation of the form used by The Association of the British Pharmaceutical Industry (ABPI), for use in Australia It is to be regarded as the basis for agreements between pharmaceutical companies sponsoring clinical studies and the institution that has oversight of the study to be conducted. Non-members of Medicinos Australia are encouraged to usethis Form of Indemnity.

	To:	Alfred Heatlh Human Research Ethics, 00 Xxxxxxxxxx Xx, Xxxxxxxxx Xxxxxxxx 0000 Austrolia, or Xxxxxx Health ABN 27 318 956 319 (“the Indemnified Party’’)
	From:	lncannex Hoalthcare Ltd 0 Xxx Xxxxxx Xxxxxxx Xxxxxxx, Xxxxxxxx 0000 Xxxxxxxxx ABN 93 096635 246 (“the Sponsor’’)
	Re:	Clinical Study No. IHLOSAPOC1: Dose finding crossover trial investigating the effect of dronabinol combined with acotazolamide on Apnoea Hypopnea Index (AHI) In adults with obstructive sleep apnoea (OSA)

1. The Indemnified Party agrees to participate in the above sponsored study (“the Study”) Involving patients of The Xxxxxx Hospital (“the Participants”) to be conducted by Xxxxxxxxx Xxxxxxx X’Xxxxx (“the lnvestigator”) in accordance with the above referenced protocol, as amended in writing from time to time with the agreement of the Sponsor and the Indemnified Party (“the Protocol”). The Sponsor confirms that It is a term of Its agreement(s) with each hospital or Institution participating In the Study that the Investigator shall obtain all necessary approvals from the Indemnified Party’s human research and ethics committee (“HREC”).

2. The Indemnified Party agrees to participate by making its HREC available lo provide review, approval and oversight of the conduct of the Study in accordance with the requirements of the NHMRC National Statement on Ethical Conduct in Human Research.

3. In consideration of such participation by the Indemnified Party, subject lo paragraph 4, the Sponsor Indemnifies and holds harmless the Indemnified Pany and its employees, agents and members of and advisors to its HREC In respect of and against all claims and proceedings (including any settlements or ex gratia payments made with the consent of the parties hereto and reasonable legal and expert costs and expenses) made or brought (whether successfully or otherwise) by or on behalf of Participants (including their dependants and children injured in utero through the participation of the child’s mother or father in the Study) against the Indemnified Party or any of its employees, agents or members of and advisors to its HREC for personal injury (including death) to Participants (and children injured in utero through the participation of the child’s mother or father in the Study) arising out of or relating to the administration and/or use of the product(s) under investigation or any clinical intervention or procedure provided for or required by the Protocol to which the Participants would not have been exposed but for the participation of the Participants in the Study.

Medicines Australia Form of Indemnity• HREC Review ONLY version 1 October 2012

Protocol Number: IHLOSAPOC1 Site: Xxxxxx Health
Medicines Australia Standard CTRA 8 March 2017 (revised)	Page 29 of 38

4. The above indemnity by the Sponsor will not apply to any such claim or proceeding referred to in paragraph 3:

(1) to the extent that such personal injury (including death) is caused by the negligent or wrongful acts or omissions or breach of statutory duty of the Indemnified Party or any of its employees, agents or members of or advisors to the HREC;

(2) unless as soon as reasonably practicable following receipt of notice of such claim or proceeding, the Indemnified Party notifies it to the Sponsor in writing and at the Sponsor’s request, and cost, has permitted the Sponsor to have full care and control of the claim or proceeding using legal representation of its own choosing; or

(3) if the Indemnified Party, its employees, agents, or members of and advisors to its HREC have made any admission in respect of any such claim or proceeding or taken any action relating to any such claim or proceeding prejudicial to the defence of any such claim or proceeding without the written consent of the Sponsor. Such consent will not be unreasonably withheld. This condition will not be treated as breached by any statement properly made by members of and advisors to the HREC in connection with the operation of the Indemnified Party’s internal complaint procedures, accident reporting and quality assurance procedures or disciplinary procedures or where such statement is required by law.

5. The Sponsor will keep the Indemnified Party and its legal advisers fully informed of the progress of any such claim or proceeding, consult fully with the Indemnified Party on the nature of any defence to be advanced and not settle any such claim or proceeding without the written approval of the Indemnified Party which approval is not to be unreasonably withheld.

6. Without prejudice to the provisions of paragraphs 4(2) and 4(3), the Indemnified Party will use reasonable endeavors to inform the Sponsor promptly of any circumstances of which it has knowledge and which may reasonably be thought likely to give rise to any such claim or proceeding and will keep the Sponsor informed of developments in relation to any such circumstances even where the Indemnified Party decides not to claim indemnity from the Sponsor. Likewise. the Sponsor will use reasonable endeavors to inform the Indemnified Party of any such circumstances and will keep the Indemnified Party informed of developments in relation to any such claim or proceeding made or brought against the Sponsor alone.

7. The Sponsor and the Indemnified Party will each give to the other such help as may reasonably be required for the efficient conduct and prompt handling of any claim or proceeding by or on behalf of Participants (including their dependants and children injured in utero through the participation of the child’s mother or father in the Study).

Medicines Australia Form of Indemnity - HREC Review ONLY version 1 October 2012

Protocol Number: IHLOSAPOC1 Site: Xxxxxx Health
Medicines Australia Standard CTRA 8 March 2017 (revised)	Page 30 of 38

8. Without prejudice to the foregoing, if injury is suffered by a Participant while participating in the Study, the Sponsor agrees to adhere to the “Guidelines for Compensation for Injury Resulting From Participation in a Company-sponsored Clinical Trial” published by Medicines Australia and will request the Investigator to make clear to the Participants that the Study is being conducted subject to those Guidelines.

9. For the purpose of this indemnity, the expression “agents” is deemed to include, but is not limited to any health professional providing services to the Indemnified Party under a contract for services or otherwise

10. This indemnity will be governed by and construed in accordance with the laws applicable in the State or Territory in which the Indemnified Party is established.

DATED the             day of           In the year

SIGNED by a duly authorised representative of the Sponsor who certifies that they have authority to sign on behalf of the Sponsor

(Signature)

(Name)

(Position)

SIGNED by the Chief Executive or a duly authorised representative of the Indemnified Party

(Signature)

(Name)

(Position)

Medicines Australia Form of Indemnity - HREC Review ONLY version 1 October 2012

Protocol Number: IHLOSAPOC1 Site: Xxxxxx Health
Medicines Australia Standard CTRA 8 March 2017 (revised)	Page 31 of 38

MEDICINES AUSTRALIA FORM OF INDEMNITY FOR CLINICAL TRIALS

STANDARD

For use where the Indemnified Party is providing premises for the conduct of the Study and HREC Review, OR is providing premises only.

To: Xxxxxx Health a body corporate established under the Health Services Xxx 0000 (Vic) of Xxxxxxxxxx Xxxx, Xxxxxxxxx, 0000 Xxxxxxxx Xxxxxxxxx or Xxxxxx Health, ABN 27 318 956 319 in which the Study is to be conducted (“the Indemnified Party”)

From: lncannex Healthcare Ltd 0 Xxx Xxxxxx Xxxxxxx Xxxxxxx, 0000 Xxxxxxxx Xxxxxxxxx ABN 93 096 635 246 (“the Sponsor”)

Re: Clinical Study No. IHLOSAPOC1: Dose Finding Crossover Trial Investigating the Effect of Dronabinol Combined with Acetazolamide on Apnoea Hypopnea Index (AHI) in Adults with Obstructive Sloop Apnoea (OSA)

1. The Indemnified Party agrees to participate in the above sponsored study (“the Study”) involving patients or the Indemnified Party (“the Participants”) to be conducted by Xxxxxxxxx Xxxxxxx X’Xxxxx (“the Investigator”) in accordance with the above referenced protocol, as amended In writing from time to time with the agreement of the Sponsor and the Indemnified Party (“the Protocol”). The Sponsor confirms that is is a term of its agreement with the Indemnified Party that the Investigator shall obtain all necessary approvals from a relevant and appropriate Human Research Ethics Committee (“HREC”) and the Indemnified Party, where appropriate. 

2.

The Indemnified Party agrees to participate by allowing the Study to be undertaken on its premises or as otherwise agreed, utilising such facilities, personnel and equipment as may reasonably be required lor the Study.

3.

In consideration or such participation by the Indemnified Party, subject lo paragraph 4, the Sponsor indemnifies and holds harmless the Indemnified Party and its employees. agents, and ii the HREC is the ethics committee of the Indemnified Party, the members of and advisors to its HREC (collectively the “Indemnified”), in respect of and against all claims and proceedings (including any settlements or ex gratia payments made with the consent of the parties hereto and reasonable legal and expert costs and expenses) made or brought (whether successfully or otherwise) by or on behalf of Participants (including their dependants and children injured in utero through the participation of the child’s mother or father in the Study) against any of the Indemnified lor personal injury (including death) to Participants (and children injured in utero through the participation of the child’s mother or father in the Study) arising out or or relating to the administration and/or use of the product(s) under investigation or any clinical intervention or procedure provided for or required by the Protocol to which the Participants would not have been exposed but lor the participation or the Participants in the Study.

Medicines Australia Fom, or Indemnity Standard version 1 October 2012

Protocol Number: IHLOSAPOC1 Site: Xxxxxx Health
Medicines Australia Standard CTRA 8 March 2017 (revised)	Page 32 of 38

4. The above indemnity by the Sponsor will not apply to any such claim or

(1) to the extent that such personal injury (including death) is caused by the negligent or wrongful acts or omissions or breach of statutory duty of the Indemnified;

(2) to the extent that such personal injury (including death) is caused by the failure of the Indemnified Party, its employees, or agents to conduct the Study strictly in accordance with the Protocol;

(3) unless as soon as reasonably practicable following receipt of notice of such claim or proceeding, the Indemnified Party notifies it to the Sponsor in writing and at the Sponsor’s request, and cost. has permitted the Sponsor to have full care and control of the claim or proceeding using legal representation of its own choosing; or

(4) if any of the Indemnified have made any admission in respect of any such claim or proceeding or taken any action relating to any such claim or proceeding prejudicial to the defence of any such claim or proceeding without the written consent of the Sponsor. Such consent will not be unreasonably withheld. This condition will not be treated as breached by any statement properly made by any of the Indemnified In connection with the operation of the Indemnified Party’s Internal complaint procedures, accident reporting and quality assurance procedures or disciplinary procedures or where such statement is required by law.

5. The Sponsor will keep the Indemnified Party and its legal advisers fully informed of the progress of any such claim or proceeding, consult fully with the Indemnified Party on the nature of any defence to be advanced and not settle any such claim or proceeding without the written approval of the Indemnified Party which approval is not to be unreasonably withheld.

6. Without prejudice to the provisions of paragraphs 4(3) and 4(4), the Indemnified Party will use reasonable endeavors to inform the Sponsor promptly of any circumstances of which it has knowledge and which may reasonably be thought likely to give rise to any such claim or proceeding and will keep the Sponsor informed of developments in relation to any such circumstances even where the Indemnified Party decides not to claim indemnity from the Sponsor. Likewise, the Sponsor will use reasonable endeavors to inform the Indemnified Party of any such circumstances and will keep the Indemnified Party informed of developments in relation to any such claim or proceeding made or brought against the Sponsor alone.

7. The Sponsor and the Indemnified Party will each give to the other such help as may reasonably be required for the efficient conduct and prompt handling of any claim or proceeding by or on behalf of Participants (including their dependants and children injured in utero through the participation of the child’s mother or father in the Study).

8. Without prejudice to the foregoing, if Injury is suffered by a Participant while participating in the Study, the Sponsor agrees to adhere to the “•Guidelines for Compensation for Injury Resulting From Participation In a Company-sponsored Clinical Trial” published by Medicines Australia and will request the Investigator to make clear to the Participants that the Study is being conducted subject to those Guidelines. and children injured in utero through the participation of the child’s mother or father in the Study).

Medicines Australia Form of Indemnity Standard version 1 October 2012

Protocol Number: IHLOSAPOC1 Site: Xxxxxx Health
Medicines Australia Standard CTRA 8 March 2017 (revised)	Page 33 of 38

8. Without prejudice to the foregoing, if injury is suffered by a Participant while participating in the Study, the Sponsor agrees to adhere to the “Guidelines for Compensation for Injury Resulting From Participation in a Company-sponsored Clinical Trial” published by Medicines Australia and will request the Investigator to make clear to the Participants that the Study is being conducted subject to those Guidelines.

9. For the purpose of this indemnity, the expression “agents” is deemed to include, but is not limited to any health professional providing services to the Indemnified Party under a contract for services or otherwise

10. This indemnity will be governed by and construed in accordance with the laws applicable in the State or Territory in which the Indemnified Party is established.

DATED the           day of         in the year

SIGNED by a duly authorised representative of the Sponsor who certifies that they have authority to sign on behalf of the Sponsor

(Signature)

(Name)

(Position)

SIGNED by the Chief Executive or a duly authorised representative of the Indemnified Party

(Signature)

(Name)

(Position)

Medicines Australia Form of Indemnity- HREC Review ONLY version 1 October 2012

Protocol Number: IHLOSAPOC1 Site: Xxxxxx Health
Medicines Australia Standard CTRA 8 March 2017 (revised)	Page 34 of 38

Schedule 4

Insurance Arrangements

Certificate of Currency

Clinical Trials Insurance Policy

Policy No:	AUS20980675A
Name Insured:	lncannHealthcare Lill
Specified Clinical Trial(s):	Dose Finding:Crossover Trial Investigating:the Effect of Dronabinol Combined with Acetezolamide on Apnoea Hypopnea Index (AHI) in Adults with Obstructive Sleep Apnoea (OSA)
Protocol Number	IHLOSAPOO
Trial Location:	Xxxxxxxxx (XXX, XXX, XXX, WA)
Period of lnsurance:	from 4pm on 1 Xxxxx 2020 to 4 pm on 1 August 2021
Limit of Liability:	AUD 20,000,000 any one Claim
Overall PolicyLimit:	AUD 20,000,000 in the annual aggregate any one Period of Insurance
Excess:	Nil
Retroactive Date:	1 August 2020
Extended Reporting: Period:	12 months (other than 72 months in respect of QLD & WA)
Territorial Limits:	Australia and New Zealand
Underwriting:	Newline Australia Insurarce Pty Ltd on behalf of Lloyds Newline Syndicate 1218 at Lloyd’s (NWL1218)
Security:
Approved by:	Xxxxx.Xxxxxxx
	/
Date:	28 July 2020

This Certificate of Currency is current at the Date of Issue only and is issued as a matter of information only, conferring no rights upon the holder. Coverage is always subject to policy terms, conditions, limitation, exclusions and endorsements. This Certificate does not extend, amend or alter such coverage.

For the avoidance of doubt, Named Insured may include other parties as defined in the Policy.

Newline Australia Insurance Pty Ltd AON 81118 089651

XX Xxx 00000, Xxxxxxx Xx Xxxx, XXX 0000

(T) 03 9999 1906 (f) 03 9670 0045

(E) xxxxx@xxxxxxxxxxxx.xxx.xx

Protocol Number: IHLOSAPOC1 Site: Xxxxxx Health
Medicines Australia Standard CTRA 8 March 2017 (revised)	Page 35 of 38

Schedule 5

Guidelines for Compensation for Injury Resulting from Participation in a Company-Sponsored Trial

Copy available online at:

xxxx://xxxxxxxxxxxxxxxxxx.xxxx.xx/xxxxxx-xxxxxxxxxxx/xxxxxxxx-xxxxxx/xxxxxxxx-xxx - compensation-guidelines/

Protocol Number: IHLOSAPOC1 Site: Xxxxxx Health
Medicines Australia Standard CTRA 8 March 2017 (revised)	Page 36 of 38

Schedule 6

Study Protocol Identification

Full Title: Dose finding crossover trial investigating the effect of dronabinol combined with acetazolamide on Apnoea Hypopnea Index (AHi) in adults with obstructive sleep apnoea (OSA)

Version Number:	4
Date:	13 / AUGUST 2020
List of Key Attachments:	NIL

Protocol Number: IHLOSAPOC1 Site: Xxxxxx Health
Medicines Australia Standard CTRA 8 March 2017 (revised)	Page 37 of 38

Schedule 7

Special Conditions

There are no special conditions.

This page is blank.

Protocol Number: IHLOSAPOC1 Site: Xxxxxx Health
Medicines Australia Standard CTRA 8 March 2017 (revised)	Page 38 of 38